Synthesis: CNS metastases in TNBC

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

Epidemiology of CNS metastases in TNBC

TNBC is the breast cancer subtype with the highest rate of CNS metastasis. Lin and colleagues at Dana-Farber, in a 2008 retrospective cohort, reported a 46% cumulative incidence of CNS metastases in metastatic TNBC patients^[1]A — substantially higher than the ~10–15% incidence in HR+/HER2− metastatic breast cancer and approximately equal to the HER2-positive metastatic rate.

Subsequent series have replicated this with somewhat variable numbers:

• Cumulative CNS metastasis incidence in metastatic TNBC: 30–45% across multiple series
• Median time from metastatic diagnosis to CNS involvement: 7–18 months
• CNS-only progression (no extracranial disease) at first metastatic recurrence: ~5–10% of metastatic TNBC patients
• Leptomeningeal carcinomatosis: ~5–10% of CNS-involved patients; particularly poor prognosis

Mechanistic hypotheses for TNBC neurotropism include preferential expression of CXCR4 and other chemokine receptors that home to brain microenvironment chemokines, blood-brain-barrier disruption associated with basal-like biology, and selective survival advantage in the brain microenvironment for cells with specific transcriptomic features^[2]B. None of these has produced a clinically actionable prevention strategy yet.

Clinical presentation

Symptoms of CNS metastases vary with location and extent:

• Headache — often the earliest symptom; usually progressive, may be worst in morning, exacerbated by positional change
• Focal neurologic deficits — weakness, sensory changes, visual disturbances, aphasia — depending on lesion location
• Seizures — ~20–30% of patients with brain metastases present with or develop seizures
• Cognitive changes / personality changes — common with frontal-lobe involvement
• Nausea and vomiting — with increased intracranial pressure
• Cranial neuropathies — with leptomeningeal involvement

Asymptomatic CNS metastases are also common, especially in patients undergoing routine imaging surveillance. The discrepancy between the high CNS metastasis rate and the relatively modest impact of routine surveillance in earlier-stage TNBC (see the recurrence-surveillance synthesis when available) reflects the trade-off between early detection and overtreatment.

Local-therapy options

Stereotactic radiosurgery (SRS)

Stereotactic radiosurgery delivers high-dose precise radiation (often a single fraction or 1–5 fractions) to individual brain lesions while sparing surrounding brain tissue. SRS is the preferred initial local therapy for patients with limited brain metastases (1–4 lesions, sometimes up to 10), particularly if lesions are surgically inaccessible or small enough to be safely targeted^[3]A.

• Local control rate: 70–90% at 1 year for lesions < 3 cm
• Neurocognitive impact: substantially less than whole-brain radiation
• Adverse events: radiation necrosis (5–15% of treated lesions), mostly manageable

Whole-brain radiation therapy (WBRT)

WBRT delivers radiation to the entire brain, treating both visible and microscopic disease. It is the standard for patients with multiple brain metastases (typically > 4–10 lesions) or for leptomeningeal carcinomatosis. WBRT has substantial neurocognitive toxicity (memory loss, attention deficits, fatigue) and is generally avoided when SRS or other targeted approaches are feasible.

Hippocampal-sparing WBRT (sparing the hippocampi during whole-brain treatment) reduces neurocognitive decline and is increasingly the standard WBRT technique^[4]B.

Surgical resection

Surgical resection is reserved for selected patients with single, surgically accessible lesions, particularly when:

• The lesion is causing mass effect / herniation risk
• Tissue diagnosis is needed (uncertainty about whether the lesion is metastasis or something else)
• The lesion is large enough that SRS would have unacceptable toxicity

Post-operative SRS to the resection cavity reduces local recurrence rates and is now standard adjuvant management after brain metastasis resection.

CNS-penetrant systemic agents

Until recently, systemic therapy options for TNBC brain metastases were limited because most chemotherapies have poor blood-brain-barrier penetration. The CNS-only progression scenario was particularly under-served: patients with controlled extracranial disease but progressing brain metastases had limited options beyond repeat local therapy.

Recent evidence has identified several CNS-active systemic agents in TNBC:

• Capecitabine — has known CNS penetration and produces response rates of 15–25% in breast cancer brain metastases^[5]B. Often given combined with local therapy.
• Sacituzumab govitecan — the ASCENT trial included brain-metastasis patients (small subset) and showed numerical benefit; the SN-38 payload has documented CNS penetration^[6]B. Real-world experience supports activity.
• Trastuzumab deruxtecan — the DESTINY-Breast trial program has shown intracranial response rates of ~30–40% in HER2-positive brain metastases (DESTINY-Breast03 sub-analyses). HER2-low TNBC brain-metastasis data are preliminary; the bystander-effect biology suggests activity is plausible.
• Tucatinib (HER2-positive precedent). Tucatinib is a HER2-directed TKI with excellent CNS penetration; the HER2CLIMB trial established it for HER2-positive brain metastases. Application to HER2-low TNBC is investigational. The tucatinib precedent established that CNS activity for HER2-targeting is feasible and motivated TNBC-specific investigations.
• Pembrolizumab — IO-treated brain metastases respond at rates somewhat lower than extracranial sites but consistent with biological activity. Most KEYNOTE-355 trial-eligible patients have stable treated brain metastases at enrollment.

Prevention strategies

Prophylactic cranial irradiation (PCI) — preemptively radiating the brain before metastases develop — has been studied in TNBC by analogy with the small-cell lung cancer experience. PCI has not been adopted in breast cancer because (a) the absolute risk of CNS metastasis, while high relative to other subtypes, is still low enough that prophylactic treatment of asymptomatic patients carries unfavorable risk-benefit, and (b) the neurocognitive toxicity of WBRT is substantial.

The HMS-RAD-1101 trial and others have investigated targeted prevention strategies in high-risk TNBC subsets; results have been hypothesis-generating but not practice-changing.

CNS-penetrant systemic therapy administered in earlier metastatic lines (or even adjuvantly) may reduce CNS-metastasis incidence as a secondary effect. The KEYNOTE-522 adjuvant pembrolizumab phase, the OlympiA adjuvant olaparib phase, and the emerging adjuvant ADC trials may have CNS-prevention benefits that haven't been fully quantified yet.

CNS-only progression — the operational challenge

A patient with metastatic TNBC who responds well to systemic therapy may have extracranial disease controlled while developing isolated CNS progression. The clinical dilemma:

• Switching systemic therapy in response to CNS-only progression may sacrifice extracranial disease control unnecessarily
• Continuing the same systemic therapy with local CNS therapy (SRS, surgery) may control the CNS lesions but doesn't prevent future CNS recurrence
• Adding a CNS-penetrant agent on top of current therapy is sometimes done; few prospective data inform this practice

The RANO-BM (Response Assessment in Neuro-Oncology Brain Metastases) criteria help standardize how CNS-only progression is defined and assessed across trials.

Evidence table

Open questions and active investigation

• Why is TNBC so neurotropic? Mechanistic hypotheses (CXCR4, cathepsin-S, basal-like biology) exist but no preventive intervention has emerged. Single-cell transcriptomics of paired primary and brain-metastatic samples is generating leads.
• CNS-active first-line metastatic therapy. Whether starting metastatic TNBC patients on a CNS-penetrant regimen (capecitabine-based combinations, certain ADCs) reduces CNS-metastasis incidence is being tested.
• T-DXd in HER2-low TNBC brain metastases. The DESTINY-Breast05 / DESTINY-Breast07 brain-met sub-analyses will inform whether T-DXd's HER2-positive CNS activity extends to HER2-low TNBC.
• Sacituzumab + radiation combinations. Combining CNS-active systemic therapy with focal radiation may produce abscopal or additive effects. Early studies underway.
• Liquid biopsy for CNS metastasis detection. Plasma ctDNA from CNS metastases may be lower-yield than extracranial sites; CSF ctDNA is more sensitive but requires lumbar puncture. The optimal monitoring approach for CNS-only progression is unresolved.
• Surgical resection in oligometastatic CNS disease. Whether aggressive local management of CNS oligometastases changes overall outcomes when combined with effective systemic therapy is a perennial question.
• Trial design. Most TNBC systemic-therapy trials still exclude active brain metastases; how to incorporate CNS-active assessment into pivotal trials is an ongoing methodological challenge.

For the broader metastatic-TNBC decision tree, see the first-line metastatic synthesis. For sacituzumab and T-DXd in metastatic TNBC generally, see the ASCENT synthesis and the T-DXd synthesis.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008;113(10):2638–2645. doi:10.1002/cncr.23930. ↩
2. Bos PD, Zhang XHF, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005–1009. doi:10.1038/nature08021. ↩
3. Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022;40(5):492–516. doi:10.1200/JCO.21.02314. ↩
4. Brown PD, Gondi V, Pugh S, et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases (NRG Oncology CC001). J Clin Oncol. 2020;38(10):1019–1029. doi:10.1200/JCO.19.02767. ↩
5. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348–1354. doi:10.1002/cncr.22127. ↩
6. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (ASCENT). N Engl J Med. 2021;384(16):1529–1541. doi:10.1056/NEJMoa2028485. ↩

Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.